Literature DB >> 19020389

Concomitant therapies (glucocorticoids and sex hormones) in adult patients with growth hormone deficiency.

C Scaroni1, F Ceccato, S Rizzati, F Mantero.   

Abstract

Adult-onset GH deficiency (GHD), mostly due to organic lesions of the pituitary-hypothalamic region, is frequently associated with multiple anterior pituitary deficiencies that need long-term substitutive treatment. The GH-IGF-I axis may play an important role in modulating peripheral metabolism of hormones (adrenal, thyroid, and sex hormones) and these interactions may have clinically significant implications on the phenotypes of adult GHD patients and on the effects of the combined replacement hormonal treatment of this condition. By accelerating the peripheral metabolism of cortisol, GH therapy may precipitate adrenal insufficiency in susceptible hypopituitary patients; estrogen replacement blunts the response to GH in women whereas in men with androgen substitution the responsivity increases over time. Endocrinologists should be mindful of these phenomena when starting patients with hypopituitarism on GH replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020389

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  5 in total

1.  Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.

Authors:  M Maccario; R Giordano; V Gasco; J Giannelli; L Campioni; E Arvat; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2022-10-17       Impact factor: 5.467

2.  Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS).

Authors:  V Rochira; G Mossetto; N Jia; S Cannavo; P Beck-Peccoz; G Aimaretti; M R Ambrosio; C Di Somma; M Losa; D Ferone; C Lubrano; C Scaroni; A Giampietro; S M Corsello; M Poggi
Journal:  J Endocrinol Invest       Date:  2018-03-13       Impact factor: 4.256

3.  Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.

Authors:  Sawako Suzuki; Yutarou Ruike; Kazuki Ishiwata; Kumiko Naito; Katsushi Igarashi; Akiko Ishida; Masanori Fujimoto; Hisashi Koide; Kentaro Horiguchi; Ichiro Tatsuno; Koutaro Yokote
Journal:  J Endocr Soc       Date:  2022-06-06

4.  Improved salivary cortisol rhythm with dual-release hydrocortisone

Authors:  Filippo Ceccato; Elisa Selmin; Chiara Sabbadin; Miriam Dalla Costa; Giorgia Antonelli; Mario Plebani; Mattia Barbot; Corado Betterle; Marco Boscaro; Carla Scaroni
Journal:  Endocr Connect       Date:  2018-09-01       Impact factor: 3.335

5.  Prader-Willi syndrome: reflections on seminal studies and future therapies.

Authors:  Michael S Chung; Maéva Langouët; Stormy J Chamberlain; Gordon G Carmichael
Journal:  Open Biol       Date:  2020-09-23       Impact factor: 6.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.